Dr. Fatima Cody Stanford and Jonathan Gruber discuss the potential of GLP-1 drugs for obesity treatment, addressing their efficacy, insurance coverage issues, and implications for the US fiscal health. They explore the disparities in Medicare coverage, complexities of drug pricing, and market competition in the healthcare industry. The episode delves into setting reasonable drug prices, innovative mechanisms for negotiation, and economic impacts of expanding coverage for GLP-1 drugs.
GLP-1 drugs target brain pathways to reduce hunger and food intake for obesity treatment.
GLP-1 medications show higher weight loss efficacy, but limited insurance coverage hinders widespread adoption.
Deep dives
GLP-1s as a Solution for Obesity
GLP-1 medications are considered a potential breakthrough in the treatment of obesity due to their focus on brain pathways regulating food intake and storage. Dr. Stanford explains that the anorexogenic pathway targeted by GLP-1s can reduce hunger and food consumption in individuals. Despite their efficacy in weight loss, these medications are not a one-size-fits-all solution for obesity treatment, with varying responses observed in different patients.
Efficacy of GLP-1 Drugs
GLP-1 drugs have evolved over decades, with varying levels of efficacy and side effects. Older anti-obesity medications approved as far back as 1933 showed limited effectiveness due to severe side effects like hyperthermia and heart issues. Modern GLP-1s like Ozempic and Trizerpitide have shown significantly higher average total body weight loss percentages, up to 22.5%, indicating improved outcomes in combating obesity.
Challenges and Economic Implications
Access to GLP-1 medications faces obstacles such as lack of insurance coverage, impacting widespread adoption. The cost implications of expanding coverage to these drugs raise concerns, with estimations showing potential significant government spending. While the economic impact of widespread GLP-1 adoption on workforce productivity is promising, the high prices of these drugs highlight the necessity for innovative pricing and investment strategies to enhance accessibility and affordability.
The newest generation of GLP-1 drugs are being hailed by some as “miracle drugs” for the treatment of obesity. But GLP-1s are expensive, insurance coverage is limited, and not everyone with obesity can and or wants to take them. In this episode, which is based on Goldman Sachs Research’s latest Top of Mind report, obesity medicine physician Dr. Fatima Cody Stanford and Jonathan Gruber, professor of economics and chairman of the Economics Department at MIT, discuss how large the addressable market for GLP-1s actually is and the implications for US fiscal health.
If you want more insights from Goldman Sachs, make sure to visit GS.com and sign up for Briefings, a weekly newsletter from Goldman Sachs about trends spanning markets, industries, and the global economy.
Get the Snipd podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share & Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode